Expert Interview
Discussing Puma Bio’s neratinib for HER2 (ERBB2)-mutant, metastatic cervical cancer
Ticker(s): PBYIAn oncologist with experience in treating cervical cancer.
Please describe your practice as a clinician, how many patients with cervical cancer do you see on a yearly basis? Could you walk us through the standard of care, and take us through the most promising upcoming treatments, or interesting clinical trials in this space?
How much of an unmet need is there in HER2 (ERBB2)-mutant, metastatic cervical cancer? How does neratinib fare, vs. competing treatment options?
How much use do you see for neratinib in the future?
In The Phase II SUMMIT trial, the ORR was 18.2% (95% CI: 5.2–40.3%) and the clinical benefit rate was 45.5% (95% CI: 24.4–67.8%), with 1 patient having a confirmed complete response, 3 patients with confirmed partial responses, and 6 patients with stable disease at equal or greater than 16 weeks. The median progression-free survival was 5.1 months (95% CI: 1.7–7.2 months). Among the 13 patients (59.1%) who had tumors with a highly activating HER2 S310F/Y mutation, 4 had confirmed responses. Could you please tell us your thoughts on those results?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
